AstraZeneca PLC (AZN)
AstraZeneca PLC (AZN) carries a ŷRobot AI score of 66 out of 100. The model's fair value estimate is $179.05, 10.5% above the last close of $162.06. The chart signal reads Sell.
| Metric | AZN |
|---|---|
| AI score | 66 / 100 |
| Chart signal | Sell |
| Fair value estimate | $179.05 |
| Upside to fair value | 10.5% |
| Previous close | $162.06 |
| P/E | 23.99 |
| Price / sales | 3.98 |
| Market cap | $246.90B |
| EPS | 6.73 |
| Revenue growth | 10.1% |
| 1-year price change | 13.7% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about AZN
Is AZN overvalued or undervalued right now?
As of Oct 14, 2026, ŷRobot's fair-value model estimates AstraZeneca PLC (AZN) at $179.05 against a last close of $162.06, implying 10.5% upside to the model's estimate.
Is AZN's chart signal bullish or bearish?
The chart-signal model classifies AZN as Neutral as of Oct 14, 2026, with a signal score of -0.12 on a -1 to 1 scale.
What is AZN's ŷRobot AI score?
AZN scores 66 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 14, 2026.
Is AZN stock expensive on P/E and P/S?
AZN trades at 24.0 times earnings and 4.0 times sales as of Oct 14, 2026.
What does AZN's seasonal forecast show?
ŷRobot's seasonal forecast curve for AZN reads -0.7% at 30 days, +2.4% at 90 days, and +13.7% at one year as of Oct 14, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is AZN growing?
AstraZeneca PLC's revenue growth is +10.1% and free-cash-flow growth is +38.1% on the latest reported figures.
AZN chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.